Uncategorized

Tasly Pharmaceuticals, Inc (Tasly) and BioHealth Innovation (BHI) co-organized the first Tasly Meeting of CEOs on Tuesday, September 2, 2014 at the Tasly facility in Rockville. Attendees included more than 25 CEOs and company representatives from local Maryland-based BioTech and BioPharma companies. This was the first public event conducted through Tasly and BHI’s newly initiated partnership.

Tasly is an innovation-based, high-tech healthcare and pharmaceutical enterprise and world-leader in the research and product development (R&D) of Chinese herbal medicine – the leader in the natural way to modernize medicine, with a North American headquarters in Rockville, Maryland, . Tasly and BHI have a formalized partnership which aims to co- organize and coordinate joint BioHealth associated events to promote professional networking, business growth, and technology and product commercialization.

The left-brain right-brain divide is bunk. And a Baltimore graduate program is celebrating that.

“We have people who have worked in the military, nonprofits, startups, started their own company, worked for huge corporations,” said Julie Buisson, a graduate assistant with the Design Leadership MBA/MA program from Johns Hopkins University’s Carey Business School and the Maryland Institute College of Art.

To say there has been change in the health care industry is an understatement. Sweeping national reform and a major shift in the way Maryland hospitals are paid are dramatically overhauling how business is done. Regardless of where you stand on Obamacare and Maryland’s Medicare waiver, you can’t ignore that reform and technology are creating lots of opportunities for innovation in a field that for too long accepted the status quo.

That’s why the Baltimore Business Journal is recognizing those innovators who are creating new health care products and strategies — whether it’s a medical device, new drug, software or a system to improve safety at the region’s hospitals. We’re looking for people and companies that are doing amazing work developing ways to make health care even more accessible, efficient and effective.

The winners of the BBJ’s 2014 Health Care Innovators will be judged for strong ideas, results and vision in several categories. Tell us why you think an innovative technology, strategy or product should be honored. How has it improved the way business is done or health care is delivered? The winners will be featured in the Nov. 7 Baltimore Business Journal and will be recognized at a special event. The BBJ will convene a panel of judges to determine the winners in the following categories:

The 2014 International Biotech Summit Committee invite BioHealth Innovation (BHI) and Montgomery County to attend the three co-located international conferences that will be held on Sep 9 -12 in Shenzhen, China:

1. 2014 International Biotech Summit (September 10, 2014);
2. The 9th International Conference on Genomics (ICG-9) (September 11th-12th, 2014);
3. Shenzhen International Biotech & Health Industry Expo 2014 (SIBHIE, September 10th-12th, 2014).

Ms. Lily Qi, Director of Special Projects for Montgomery County Executive Office who was involved in establishing BHI and a native of Shanghai, is going to speak on behalf of the County and BHI for the forum, “Innovation in Policy and Regulation for Advancing Healthcare Industry.” BHI and the County are also invited as an exhibitor for the SIBHIE Expo.

– Representatives from Sigma-Tau Pharmaceuticals Inc., Alexandria Real Estate Equities, Inc., and Deloitte Consulting LLP Take New Board Seats – 

– Charles Morton Becomes New Venable LLP Representative on Board while Mike Baader Stays on as Board Member (Now as Greenspring Associates Representative) –

ROCKVILLE AND BALTIMORE, MARYLAND, August 11, 2014 – BioHealth Innovation, Inc. (BHI) announced today the appointment of four new members to its Board of Directors. Dave Lemus, Chief Executive Officer, Sigma-Tau Pharmaceuticals Inc.; Joel S. Marcus, Chairman, Chief Executive Officer, and Founder, Alexandria Real Estate Equities, Inc. (Alexandria Venture Investments); and Beth Meagher, Principal, Deloitte Consulting LLP, have joined the BHI Board of Directors, effective August 7, 2014, based upon their organizations’ newly committed support of BHI. Charles “Chuck” Morton now represents Venable LLP on the Board, as another new Board member, while Mike Baader, formerly with Venable, will continue to hold a seat on the Board, but now as a representative of Greenspring Associates. Cynthia L. Collins, CEO, Clarient, who had served on the BHI Board since early 2013, is stepping down from her Board position after relocating to the West Coast

“The expansion of and continued diversity within the BHI Board, based upon new key industry and service provider representatives who are all deeply involved in life sciences, is a testament to the positive impact BHI has made on the Central Maryland biohealth community to date,” said Richard Bendis, BHI President & CEO. 

“We look forward to the contributions from the new Board members representing these organizations. We’re also pleased to welcome a new Venable representative to the Board and that Mike Baader will continue to add value to the organization now that he is on the Greenspring Associates team,” said Douglas Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. “And, on behalf of the BHI staff and Board, I would also like to offer gratitude to Cynthia Collins for her service and contributions to the BHI Board over the last year and half.”